Next Sequence

www.thenextsequence.vc

VCMatch tracks Next Sequence as an investor focused on AI/ML and Biotech companies and $125m check sizes. Upload your deck to compare your startup against the full private matching profile.

Check Size

$125m

Stages

Not specified

Focus Areas

AI/ML, Biotech

Geography

Not specified

Investment Thesis

This firm positions itself as a specialist investor backing companies that are “building and scaling a future powered by AI and Biology®.” They combine capital with operational support (noted by “20+ people Operating Partners & Associates”) and pursue an explicit growth target (“$125 million Invested capital target by 2030”), indicating a hands-on, growth-oriented thesis focused on transformational, platform-level convergence of AI and biology. They are also explicitly founder‑facing and open to inbound deal flow: “Pitch your startup” / “Become our next AI and Biology® portfolio company.”

Is Next Sequence right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

Next Sequence is most relevant for founders raising venture-backed rounds in AI/ML and Biotech, with public check-size signals around $125m.

Focus statement

The firm focuses exclusively on "AI and Biology®" companies that "shape the future of humanity," aiming to invest in and scale startups at the intersection of artificial intelligence and biological science.

Value Add

Branded, sector-specific thesis: the trademarked focus on "AI and Biology®" (unique positioning at the AI × biology intersection).
Operational depth: claims "20+ people Operating Partners & Associates", implying hands-on post‑investment support.
Ambitious, time‑bound capital target: "$125 million Invested capital target by 2030", signaling a defined deployment plan.
Selective / concentrated portfolio to date: only "6 startups" in the portfolio, suggesting focus and deeper engagement per company.
Founder accessibility: explicit call-to-action — "Pitch your startup" / "Become our next AI and Biology® portfolio company."